Long vs Short Acting Testosterone Treatments: A Look at the Risks - 09/02/23

Résumé |
Prescriptions for testosterone therapy (TT) to treat testosterone deficiency have increased in recent years. The purpose of this review was to evaluate the risks of several treatment modalities to better counsel patients. Both short-acting and long-acting TT has been shown to restore normal serum testosterone levels and improve symptoms of testosterone deficiency. Short-acting pharmacology mimics normal physiology more closely than long-acting TT but requires multiple doses per day. Long-acting TT has a higher rate of patient adherence but is more likely to create supraphysiologic serum testosterone and pathologic sequelae.
Le texte complet de cet article est disponible en PDF.Abbreviations : TT, T, IM, SQ
Plan
| Financial Disclosure: The authors declare that they have no relevant financial interests. |
|
| Declarations of interest: None. |
|
| Funding: This work was supported by National Institutes of Health Grant R01 DK130991-01. |
Vol 172
P. 5-12 - février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
